<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02163447</url>
  </required_header>
  <id_info>
    <org_study_id>PROMOTE-BC1</org_study_id>
    <secondary_id>P01HD059454</secondary_id>
    <nct_id>NCT02163447</nct_id>
  </id_info>
  <brief_title>Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants</brief_title>
  <acronym>PROMOTE-BC1</acronym>
  <official_title>Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double-blinded randomized controlled phase III trial of 300 HIV uninfected
      pregnant women and the children born to them. The study interventions will be divided into
      two phases. In the first phase, HIV uninfected women at 12-20 weeks gestation will be
      randomized in equal proportions to one of three intermittent preventive therapy in pregnancy
      (IPTp) treatment arms: 1) 3 doses of sulfadoxine-pyrimethamine (SP), 2) 3 doses of
      dihydroartemisinin-piperaquine (DP), or 3) monthly DP. All three interventions arms will have
      either SP or DP placebo to ensure adequate blinding is achieved. Follow-up for the pregnant
      women will end approximately 6 weeks after giving birth. In the second phase of the study,
      all children born to mothers enrolled in the study will be followed from birth until they
      reach 36 months of age. Children born to mothers randomized to receive 3 doses of SP during
      pregnancy will receive DP every 3 months between 2-24 months of age. Children born to mothers
      randomized to receive 3 doses of DP or monthly DP during pregnancy will receive either DP
      every 3 months or monthly DP between 2-24 months of age. To ensure adequate blinding,
      children who will receive DP every 3 months will be given DP placebo during the months they
      will not be taking DP. Children will then be followed an additional year between 24-36 months
      of age following the interventions. We will test the hypothesis that IPT with DP will
      significantly reduce the burden of malaria in pregnancy and infancy and improve the
      development of naturally acquired antimalarial immunity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women will be scheduled to be seen in the clinic every 4 weeks during their
      pregnancy and 6 weeks following delivery. In addition, pregnant women will be instructed to
      come to the study clinic for all their medical care and avoid the use of any outside
      medications. Children will be scheduled to be seen in the clinic every 4 weeks and parents
      /guardians of children will be instructed to bring their child to the study clinic for all
      medical care and avoid the use of any outside medications. The study clinic will remain open
      7 days a week from 8 a.m. to 5 p.m.

      Each time a study participant is seen in the clinic a standardized history and physical exam
      will be performed. Patients who are febrile (tympanic temperature &gt; 3 8.0ËšC) or report
      history of fever in the past 24 hours will have blood obtained by finger prick for a thick
      blood smear. If the thick blood smear is positive, the patient will be diagnosed with
      malaria. If the thick blood smear is negative, the patient will be managed by study
      physicians for a non-malarial febrile illness. If the patient is afebrile and does not report
      a recent fever, a thick blood smear will not be obtained, except when following routine
      testing schedules.

      Routine assessments will be done in the clinic every 4 weeks for both pregnant women and
      children. Pregnant women and children will receive standards of care as designated in the
      Uganda MOH guidelines. Routine care in children will use Integrated Management of Childhood
      Illness (IMCI) guidelines. During routine assessments subjects will be asked about visits to
      outside health facilities and the use of any medications outside the study protocol.
      Standardized assessment of adherence will also be done for study drugs administered at home
      and Insecticide Treated Net use. A routine history and physical exam will be performed using
      a standardized clinical assessment form. Blood will be collected by finger prick for thick
      smear, collection of plasma for PK studies, and filter paper samples. Phlebotomy for routine
      laboratory tests (CBC and ALT) to monitor for potential adverse events from study medications
      and for immunology studies will be performed every 8 weeks in pregnant women and every 16
      weeks in children. Non malaria screening will also include stool ova and parasite
      examination, circulating filarial antigens (by ICT card for Wucheria), and blood smear for
      microfilaremia (including Mansonella perstans) using Knott's technique. For pregnant women
      and children 2-24 months of age, study drugs will be administered at the time of each routine
      visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 23, 2014</start_date>
  <completion_date type="Actual">May 14, 2018</completion_date>
  <primary_completion_date type="Actual">May 14, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of Placental Malaria</measure>
    <time_frame>Delivery</time_frame>
    <description>Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Malaria in Pregnant Women</measure>
    <time_frame>Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination</time_frame>
    <description>Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Malaria in Infants</measure>
    <time_frame>Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age) and at 24 months of age and will end when study participants reaches 36 months of age or termination</time_frame>
    <description>Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP</measure>
    <time_frame>Delivery</time_frame>
    <description>Prevalence of placental blood samples positive for parasites by microscopy or LAMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery</measure>
    <time_frame>At delivery</time_frame>
    <description>Prevalence of maternal parasitemia at delivery by microscopy and LAMP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (&lt;2500g), Still Birth, Pre-term Delivery</measure>
    <time_frame>Delivery</time_frame>
    <description>Congenital malformations, spontaneous abortion, LBW (&lt;2500g), still birth, pre-term delivery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Anemia in Pregnant Women</measure>
    <time_frame>After first dose of study drugs up to delivery or early termination</time_frame>
    <description>Prevalence of routine hemoglobin measurements &lt; 11 g/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Complicated Malaria in Infants</measure>
    <time_frame>Birth up to 24 months of age or early study termination</time_frame>
    <description>Any treatment for malaria meeting criteria for severe malaria or danger signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hospital Admissions in Infants</measure>
    <time_frame>Birth up to 24 months of age or early study termination</time_frame>
    <description>Admission to a hospital for pediatric inpatient care for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Gametocytemia in Pregnant Women and Infants</measure>
    <time_frame>Women: Gestational age between 12-20 weeks (at study entry) up to delivery; Infants: Birth up to 24 months of age or early study termination</time_frame>
    <description>Proportion of routine blood smears positive for gametocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Parasitemia in Infants</measure>
    <time_frame>Birth up to 24 months of age or early study termination</time_frame>
    <description>Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy</measure>
    <time_frame>After first dose of study drug through delivery or early termination</time_frame>
    <description>Detection of malaria parasites by LAMP during pregnancy</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Malaria</condition>
  <arm_group>
    <arm_group_label>3 dose SP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 dose DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 dose DP pregnancy / monthly DP infancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monthly DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>monthly DP pregnancy / monthly DP infancy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy</intervention_name>
    <arm_group_label>monthly DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_label>monthly DP pregnancy / monthly DP infancy</arm_group_label>
    <other_name>Duo-Cotexin (Holley-Cotec)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy</intervention_name>
    <arm_group_label>3 dose DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_label>3 dose DP pregnancy / monthly DP infancy</arm_group_label>
    <other_name>Duo-Cotexin (Holley-Cotec)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy</intervention_name>
    <arm_group_label>3 dose SP pregnancy / 3 monthly DP infancy</arm_group_label>
    <other_name>Kamsidar (KPI)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Monthly dihydroartemisinin-piperaquine (DP) for infants</intervention_name>
    <arm_group_label>3 dose DP pregnancy / monthly DP infancy</arm_group_label>
    <arm_group_label>monthly DP pregnancy / monthly DP infancy</arm_group_label>
    <other_name>Duo-Cotexin (Holley-Cotec)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3-monthly dihydroartemisinin-piperaquine (DP) for infants</intervention_name>
    <arm_group_label>3 dose DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_label>3 dose SP pregnancy / 3 monthly DP infancy</arm_group_label>
    <arm_group_label>monthly DP pregnancy / 3 monthly DP infancy</arm_group_label>
    <other_name>Duo-Cotexin (Holley-Cotec)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by
             ultrasound

          2. Estimated gestational age between 12-20 weeks

          3. Confirmed to be HIV uninfected by rapid test

          4. 16 years of age or older

          5. Residency within 30km of the study clinic

          6. Provision of informed consent by the pregnant woman for herself and her unborn child

          7. Agreement to come to the study clinic for any febrile episode or other illness and
             avoid medications given outside the study protocol

          8. Plan to deliver in the hospital

        Exclusion Criteria:

          1. History of serious adverse event to SP or DP

          2. Active medical problem requiring inpatient evaluation at the time of screening

          3. Intention of moving more than 30km from the study clinic

          4. Chronic medical condition requiring frequent medical attention

          5. Prior SP preventive therapy or any other antimalarial therapy during this pregnancy

          6. Early or active labor (documented by cervical change with uterine contractions)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grant Dorsey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Diane V Havlir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moses Kamya, MBChB, MMed, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Makerere University; Infectious Diseases Research Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IDRC Research Clinic -Tororo District Hospital</name>
      <address>
        <city>Tororo</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Uganda</country>
  </location_countries>
  <results_reference>
    <citation>Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Opira B, Olwoch P, Ategeka J, Nayebare P, Clark TD, Feeney ME, Charlebois ED, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. N Engl J Med. 2016 Mar 10;374(10):928-39. doi: 10.1056/NEJMoa1509150.</citation>
    <PMID>26962728</PMID>
  </results_reference>
  <results_reference>
    <citation>Muhindo MK, Kakuru A, Natureeba P, Awori P, Olwoch P, Ategeka J, Nayebare P, Clark TD, Muehlenbachs A, Roh M, Mpeka B, Greenhouse B, Havlir DV, Kamya MR, Dorsey G, Jagannathan P. Reductions in malaria in pregnancy and adverse birth outcomes following indoor residual spraying of insecticide in Uganda. Malar J. 2016 Aug 26;15(1):437. doi: 10.1186/s12936-016-1489-x.</citation>
    <PMID>27566109</PMID>
  </results_reference>
  <results_reference>
    <citation>Conrad MD, Mota D, Foster M, Tukwasibwe S, Legac J, Tumwebaze P, Whalen M, Kakuru A, Nayebare P, Wallender E, Havlir DV, Jagannathan P, Huang L, Aweeka F, Kamya MR, Dorsey G, Rosenthal PJ. Impact of Intermittent Preventive Treatment During Pregnancy on Plasmodium falciparum Drug Resistance-Mediating Polymorphisms in Uganda. J Infect Dis. 2017 Nov 15;216(8):1008-1017. doi: 10.1093/infdis/jix421.</citation>
    <PMID>28968782</PMID>
  </results_reference>
  <results_reference>
    <citation>Kapisi J, Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, Ssekitoleko R, Olwoch P, Ategeka J, Nayebare P, Clark TD, Rizzuto G, Muehlenbachs A, Havlir DV, Kamya MR, Dorsey G, Gaw SL. Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J. 2017 Oct 5;16(1):400. doi: 10.1186/s12936-017-2040-4.</citation>
    <PMID>28982374</PMID>
  </results_reference>
  <results_reference>
    <citation>Jagannathan P, Kakuru A, Okiring J, Muhindo MK, Natureeba P, Nakalembe M, Opira B, Olwoch P, Nankya F, Ssewanyana I, Tetteh K, Drakeley C, Beeson J, Reiling L, Clark TD, Rodriguez-Barraquer I, Greenhouse B, Wallender E, Aweeka F, Prahl M, Charlebois ED, Feeney ME, Havlir DV, Kamya MR, Dorsey G. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med. 2018 Jul 17;15(7):e1002606. doi: 10.1371/journal.pmed.1002606. eCollection 2018 Jul.</citation>
    <PMID>30016328</PMID>
  </results_reference>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <results_first_submitted>August 17, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2018</results_first_posted>
  <last_update_submitted>November 13, 2018</last_update_submitted>
  <last_update_submitted_qc>November 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Grant Dorsey, M.D, Ph.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Chemoprevention</keyword>
  <keyword>Malaria</keyword>
  <keyword>Uganda</keyword>
  <keyword>Sulfadoxine-pyrimethamine</keyword>
  <keyword>Dihydroartemisinin-piperaquine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malaria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Sulfadoxine</mesh_term>
    <mesh_term>Piperaquine</mesh_term>
    <mesh_term>Fanasil, pyrimethamine drug combination</mesh_term>
    <mesh_term>Dihydroartemisinin</mesh_term>
    <mesh_term>Artemisinins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/47/NCT02163447/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mothers - 3 Dose SP</title>
          <description>Sulfadoxine-Pyrimethamine 500mg/25mg</description>
        </group>
        <group group_id="P2">
          <title>Mothers - 3 Dose DP</title>
          <description>Dihydrioartemisinin-Piperaquine 40mg/320mg</description>
        </group>
        <group group_id="P3">
          <title>Mothers - Monthly DP</title>
          <description>Dihydroartemisinin-Piperaquine 20mg/160mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved out of study area</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Became HIV infected at time of delivery</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mothers - 3 Dose SP</title>
          <description>Sulfadoxine-Pyrimethamine 500mg/25mg</description>
        </group>
        <group group_id="B2">
          <title>Mothers - 3 Dose DP</title>
          <description>Dihydrioartemisinin-Piperaquine 40mg/320mg</description>
        </group>
        <group group_id="B3">
          <title>Mothers - Monthly DP</title>
          <description>Dihydroartemisinin-Piperaquine 20mg/160mg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="106"/>
            <count group_id="B2" value="94"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="300"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="3.6"/>
                    <measurement group_id="B2" value="22.2" spread="4.3"/>
                    <measurement group_id="B3" value="22.6" spread="4.0"/>
                    <measurement group_id="B4" value="22.0" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="100"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gestation (weeks)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>12 to 16 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="67"/>
                    <measurement group_id="B4" value="207"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 16 to 20 wk</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gravidity</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;= 3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bed-net ownership</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>None</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Untreated Net</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Long lasting insecticide- treated net</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Household wealth index</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Lowest third</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Middle third</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Highest third</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="6.8"/>
                    <measurement group_id="B2" value="55.6" spread="7.0"/>
                    <measurement group_id="B3" value="55.5" spread="7.5"/>
                    <measurement group_id="B4" value="55.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="162.8" spread="6.8"/>
                    <measurement group_id="B2" value="162.5" spread="6.7"/>
                    <measurement group_id="B3" value="162.3" spread="7.7"/>
                    <measurement group_id="B4" value="162.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>White blood cells per mm^3</title>
          <units>cells per mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6036" spread="2070"/>
                    <measurement group_id="B2" value="6279" spread="1713"/>
                    <measurement group_id="B3" value="6040" spread="1572"/>
                    <measurement group_id="B4" value="6113" spread="1802"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Neutrophil cells per mm^3</title>
          <units>cells per mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3330" spread="1477"/>
                    <measurement group_id="B2" value="3558" spread="1304"/>
                    <measurement group_id="B3" value="3351" spread="1175"/>
                    <measurement group_id="B4" value="3409" spread="1327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet cells per mm^3</title>
          <units>cells per mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="198906" spread="60665"/>
                    <measurement group_id="B2" value="201809" spread="67358"/>
                    <measurement group_id="B3" value="195840" spread="59593"/>
                    <measurement group_id="B4" value="198793" spread="62332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin level g/dL</title>
          <units>g/DL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.8" spread="1.5"/>
                    <measurement group_id="B2" value="11.9" spread="1.1"/>
                    <measurement group_id="B3" value="12.0" spread="1.4"/>
                    <measurement group_id="B4" value="11.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase level IU/L</title>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.4" spread="7.5"/>
                    <measurement group_id="B2" value="14.9" spread="5.8"/>
                    <measurement group_id="B3" value="14.7" spread="5.6"/>
                    <measurement group_id="B4" value="15.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Detection of malaria parasites by LAMP</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="43"/>
                    <measurement group_id="B4" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No sample collected</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prevalence of Placental Malaria</title>
        <description>Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.</description>
        <time_frame>Delivery</time_frame>
        <population>Only women who delivered and had histopathology results were analyzed. 2 women in 3 Dose SP and 1 woman in monthly DP arms completed the study but did not have histopathology results.</population>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Placental Malaria</title>
          <description>Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.</description>
          <population>Only women who delivered and had histopathology results were analyzed. 2 women in 3 Dose SP and 1 woman in monthly DP arms completed the study but did not have histopathology results.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Malaria in Pregnant Women</title>
        <description>Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
        <time_frame>Time at risk will begin after first dose of study drug and will end when study participants deliver or early study termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Sulfadoxine-Pyrimethamine 500mg/25mg</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Dihydrioartemisinin-Piperaquine 40mg/320mg</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Dihydroartemisinin-Piperaquine 20mg/160mg</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Malaria in Pregnant Women</title>
          <description>Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.</description>
          <units>events per person years</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95"/>
                    <measurement group_id="O2" value="0.31"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Malaria in Infants</title>
        <description>Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age.</description>
        <time_frame>Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age) and at 24 months of age and will end when study participants reaches 36 months of age or termination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP</title>
        <description>Prevalence of placental blood samples positive for parasites by microscopy or LAMP</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Blood Samples Positive for Parasites by Microscopy or LAMP</title>
          <description>Prevalence of placental blood samples positive for parasites by microscopy or LAMP</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="88"/>
                <count group_id="O3" value="96"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Micropscopic assessment of placental blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMP assessment of placental blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery</title>
        <description>Prevalence of maternal parasitemia at delivery by microscopy and LAMP</description>
        <time_frame>At delivery</time_frame>
        <population>One observation in the monthly DP arm did not have results for microscopy; this outcome measure tests blood taken from the mother's arm (different from outcome measure 4 which tests blood taken from the placenta)</population>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Sulfadoxine-Pyrimethamine 500mg/25mg</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Dihydrioartemisinin-Piperaquine 40mg/320mg</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Dihydroartemisinin-Piperaquine 20mg/160mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Maternal Blood Samples Positive for Parasites by Microscopy and LAMP at Delivery</title>
          <description>Prevalence of maternal parasitemia at delivery by microscopy and LAMP</description>
          <population>One observation in the monthly DP arm did not have results for microscopy; this outcome measure tests blood taken from the mother's arm (different from outcome measure 4 which tests blood taken from the placenta)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Microscopy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="97"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LAMP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                    <count group_id="O2" value="89"/>
                    <count group_id="O3" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (&lt;2500g), Still Birth, Pre-term Delivery</title>
        <description>Congenital malformations, spontaneous abortion, LBW (&lt;2500g), still birth, pre-term delivery</description>
        <time_frame>Delivery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Birth Outcomes: Congenital Malformations, Spontaneous Abortion, LBW (&lt;2500g), Still Birth, Pre-term Delivery</title>
          <description>Congenital malformations, spontaneous abortion, LBW (&lt;2500g), still birth, pre-term delivery</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="89"/>
                <count group_id="O3" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Anemia in Pregnant Women</title>
        <description>Prevalence of routine hemoglobin measurements &lt; 11 g/dL</description>
        <time_frame>After first dose of study drugs up to delivery or early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Anemia in Pregnant Women</title>
          <description>Prevalence of routine hemoglobin measurements &lt; 11 g/dL</description>
          <units>hemoglobin measurements taken every 12wk</units>
          <param>Number</param>
          <units_analyzed>hemoglobin measurements taken every 12wk</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>hemoglobin measurements taken every 12wk</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="258"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="72"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Complicated Malaria in Infants</title>
        <description>Any treatment for malaria meeting criteria for severe malaria or danger signs</description>
        <time_frame>Birth up to 24 months of age or early study termination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hospital Admissions in Infants</title>
        <description>Admission to a hospital for pediatric inpatient care for any reason</description>
        <time_frame>Birth up to 24 months of age or early study termination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Gametocytemia in Pregnant Women and Infants</title>
        <description>Proportion of routine blood smears positive for gametocytes</description>
        <time_frame>Women: Gestational age between 12-20 weeks (at study entry) up to delivery; Infants: Birth up to 24 months of age or early study termination</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Parasitemia in Infants</title>
        <description>Proportion of routine monthly samples positive for parasites by LAMP. Proportion of routine samples (LAMP or blood smears) positive for asexual parasites.</description>
        <time_frame>Birth up to 24 months of age or early study termination</time_frame>
        <posting_date>10/2018</posting_date>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy</title>
        <description>Detection of malaria parasites by LAMP during pregnancy</description>
        <time_frame>After first dose of study drug through delivery or early termination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mothers - 3 Dose SP</title>
            <description>Sulfadoxine-Pyrimethamine 500mg/25mg</description>
          </group>
          <group group_id="O2">
            <title>Mothers - 3 Dose DP</title>
            <description>Dihydrioartemisinin-Piperaquine 40mg/320mg</description>
          </group>
          <group group_id="O3">
            <title>Mothers - Monthly DP</title>
            <description>Dihydroartemisinin-Piperaquine 20mg/160mg</description>
          </group>
        </group_list>
        <measure>
          <title>Prevalence of Parasitemia at the Time of Monthly Routine Visits During Pregnancy</title>
          <description>Detection of malaria parasites by LAMP during pregnancy</description>
          <units>LAMP measurement</units>
          <param>Number</param>
          <units_analyzed>LAMP measurement</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
                <count group_id="O2" value="94"/>
                <count group_id="O3" value="100"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>LAMP measurement</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="509"/>
                <count group_id="O2" value="445"/>
                <count group_id="O3" value="496"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study drug initiation to 6 weeks postpartum or last observed date in study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mothers - 3 Dose SP</title>
          <description>Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
        <group group_id="E2">
          <title>Mothers - 3 Dose DP</title>
          <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
3-monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
        <group group_id="E3">
          <title>Mothers - Monthly DP</title>
          <description>Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP.
Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age.
3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Monthly dihydroartemisinin-piperaquine (DP) for infants</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Preeclampsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital Anomaly</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Threatened Abortion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="90" subjects_at_risk="106"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="94"/>
                <counts group_id="E3" subjects_affected="89" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="106"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="13" subjects_affected="10" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="106"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="172" subjects_affected="74" subjects_at_risk="106"/>
                <counts group_id="E2" events="122" subjects_affected="58" subjects_at_risk="94"/>
                <counts group_id="E3" events="132" subjects_affected="73" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="94" subjects_affected="55" subjects_at_risk="106"/>
                <counts group_id="E2" events="71" subjects_affected="48" subjects_at_risk="94"/>
                <counts group_id="E3" events="77" subjects_affected="57" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="90" subjects_affected="56" subjects_at_risk="106"/>
                <counts group_id="E2" events="70" subjects_affected="45" subjects_at_risk="94"/>
                <counts group_id="E3" events="78" subjects_affected="55" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="106"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E3" events="12" subjects_affected="11" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="106"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="14" subjects_affected="13" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="106"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="106"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Grant Dorsey</name_or_title>
      <organization>UCSF</organization>
      <phone>415-206-4680</phone>
      <email>grant.dorsey@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

